

# PKU- Palynziq Adult Male

Stephanie Hacker, MS, RDN, LDN, CNSC, CSSD



# Patient information

- Diagnosis
  - Phenylketonuria
- Age at diagnosis
  - 3 weeks
- Current age
  - 19 years
- Relevant medications
  - Palynziq 40 mg/d (Therapy started 2019)
  - Zyrten (Ceterizine)- 10 mg
  - Pepcid (Famotidine)- 10 mg
- Relevant procedures
  - NA
- Any other important demographic details
  - Lives with Mom – Prepares dinner
  - Works at a warehouse facility from 8a-4p M-F – Lunch Provided
  - Not currently enrolled in college classes – due to COVID



# Patient information

- Relevant Labs
  - Phe levels since starting Palynziq

Day	Phe Levels	Phe levels
Day 1 (Palynziq started)	1039 (17.3)	34
Day 14	1155 (19.3)	49
Day 38 (10 mg started)	1299 (21.7)	46
Day 52	461 (7.7)	29
Day 70 (20mg started day 66)	902 (15)	35
Day 75	837 (13.8)	36
Day 83	629 (10.4)	38
Day 100	644 (10.7)	31
Day 114	679 (11.3)	29
Day 135	767 (12.8)	31
Day 154	703 (11.7)	33
Day 185	803 (13.4)	31
Day 233	776 (12.9)	32

Day (continued)	Phe levels	Phe levels
Day 247	821 (13.6)	36
Day 261	840 (14)	32
Day 273 (started 40mg day 270))	711 (11.9)	31
Day 285	495 (8.25)	30
Day 325	683 (11.4)	32
Day 362	647 (10.8)	32
Day 392	470 (7.9)	37
Day 470	30 (0.5)	43
Day 489	19 (0.3)	33
Day 506	25 (0.4)	33
Day 524	334 (5.6)	37
Day 543	602 (10.2)	41
4/19/21	787 (13.2)	39



# Patient information

- Underlying medical conditions that make patient more susceptible to COVID (if applicable)
  - No
- Sociological considerations around COVID-19 risk (Compliant mask wearing? Frontline worker not able to stay home? Intergenerational household? etc.)
  - Works in warehouse- Reports compliance with mask wearing at work, but eats indoors with coworkers
  - Plays basketball with friends, does not wear mask
  - Lives with mom
- Did the patient ever test positive for COVID-19?
  - No



# Vaccination History

- Did the patient receive the vaccine?- If yes, which one?
  - Johnson and Johnson
- Did the patient experience any reactogenicity to the vaccine?- If yes, which reactions? How were they managed?
  - Reported hair loss and “itchiness” one week prior to injection
    - Did not report worsening of symptoms following vaccine
  - Headache reported one day following vaccine
- Did the patient ask any questions about the vaccine or did they voice any concerns?- If yes, how did you respond?
  - Patient did not ask about vaccine but informed us he received it 1 week after injection.



# Other Observations

- Are there any published guidelines you referenced around this condition and the vaccine or COVID-19? (if applicable)
  - NPKUA and Biomarin both released letters to discuss vaccination with your medical provider
- Are there any other considerations related to COVID-19 that people with this condition should keep in mind going forward? (if applicable)
  - It is our clinics belief that patients with PKU are not at increased risk of developing severe COVID-19

